Tag Archives: Dewey Steadman

Aceto Corp Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Aceto Corp (NASDAQ: ACET) today and set a price target of $10. The company’s shares opened today at $7.20, close to its 52-week low of $7.06. Steadman commented: “We are

Canaccord Genuity Remains a Hold on Pacira Pharmaceuticals

Canaccord Genuity analyst Dewey Steadman reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) yesterday and set a price target of $32. The company’s shares closed on Wednesday at $36.10. According to TipRanks.com, Steadman is ranked 0 out of 5

Canaccord Genuity Thinks Aceto Corp’s Stock is Going to Recover

In a report released yesterday, Dewey Steadman from Canaccord Genuity reiterated a Buy rating on Aceto Corp (NASDAQ: ACET), with a price target of $10. The company’s shares closed on Friday at $7.92, close to its 52-week low of $7.77.

Canaccord Genuity Sticks to Its Buy Rating for Aerie Pharma

Canaccord Genuity analyst Dewey Steadman reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI) yesterday and set a price target of $86. The company’s shares closed yesterday at $55.50. According to TipRanks.com, Steadman is a 1-star analyst with an average

Canaccord Genuity Believes Perrigo Company plc (NYSE: PRGO) Still Has Room to Grow

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Perrigo Company plc (NYSE: PRGO) on January 15 and set a price target of $100. The company’s shares closed yesterday at $90.86, close to its 52-week high of $92.75. According

Canaccord Genuity Releases a Buy Rating on Lipocine

In a report issued on January 8, Dewey Steadman from Canaccord Genuity assigned a Buy rating to Lipocine (NASDAQ: LPCN), with a price target of $11. The company’s shares closed yesterday at $3.46. Steadman observed: “We eagerly anticipate Wednesday’s meeting